Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...
William Blair initiated coverage of Vigil Neuroscience (VIGL) with an Outperform rating and $18.67 fair value estimate. Vigil is developing a ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of ...
Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of ...